You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
While the Oxford, UK-based company has focused on drug development partnerships to date, it is also keen to see uptake of genetic disease risk screening by the NHS.
Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
The funding is part of a Small Business Research Initiative competition to promote the development of new technologies to advance the diagnostic application of genomic screening.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.